CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.82B, above the global median of $1.15B
- FinancialsLow earnings quality
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
12.21BCNY1.82B · vs all stocks (USD)
Revenue (TTM)
759.63MCNY112.96M · vs all stocks (USD)
Profit Margin
-3.13%vs Biotechnology peers
52-Week Change
-9.41%vs all stocks
Market Capitalization
12.21BCNY1.82B · vs all stocks (USD)
Enterprise Value
11.37BCNY1.69B · vs all stocks (USD)
Price to Sales (TTM)
16.17xvs Biotechnology peers
Price to Book (MRQ)
13.20xvs Biotechnology peers
Enterprise to Revenue
14.96xvs Biotechnology peers
Enterprise to EBITDA
94.81xvs Biotechnology peers
Gross Margin
91.84%vs Biotechnology peers
Profit Margin
-3.13%vs Biotechnology peers
Operating Margin
20.17%vs Biotechnology peers
Return on Assets (TTM)
2.62%vs Biotechnology peers
Return on Equity (TTM)
-2.68%vs Biotechnology peers
Revenue (TTM)
759.63MCNY112.96M · vs all stocks (USD)
Revenue per Share (TTM)
1.87CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-6.80%vs Biotechnology peers
Gross Profit (TTM)
687.28MCNY102.21M · vs all stocks (USD)
EBITDA (TTM)
112.11MCNY16.67M · vs all stocks (USD)
Net Income (TTM)
-23.81MCNY-3.54M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-21.96%vs Biotechnology peers
Operating Cash Flow (TTM)
54.83MCNY8.15M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
20.69MCNY3.08M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
300.98KCNYFY2025 · Dec 31, 2025Revenue
704.16MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
49.58MCNYFY2025 · Dec 31, 2025Gross Profit
654.58MCNYFY2025 · Dec 31, 2025Operating Income
71.45MCNY10.63M · vs all stocks (USD)
Pre-tax Income
31.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.99MCNYFY2025 · Dec 31, 2025Net Income
21.90MCNYFY2025 · Dec 31, 2025EBIT
46.54MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
112.11MCNYFY2025 · Dec 31, 2025Research & Development
132.90MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
330.99MCNYFY2025 · Dec 31, 2025Other Operating Expenses
81.21MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
603.56KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
14.64MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
21.90MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
361.40KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-34.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
-133.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
225.18MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
21.90MCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.09MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-84.65MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.95MCNYFY2025 · Dec 31, 2025Capital Expenditures
-98.78MCNYFY2025 · Dec 31, 2025Purchase of Investments
-224.21MCNYFY2025 · Dec 31, 2025Sale of Investments
200.50MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-122.49MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
176.10MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-114.72MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-14.72MCNYFY2025 · Dec 31, 2025Other Financing Charges
-22.26MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
24.40MCNYFY2025 · Dec 31, 2025Shares Outstanding
405.93MSharesUpdated Aug 21, 2026Float Shares
248.50MSharesUpdated Aug 21, 2026% Held by Insiders
38.43%vs all stocks
% Held by Institutions
9.76%vs all stocks
Total Cash (MRQ)
235.28MCNY34.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5800CNYUpdated Aug 21, 2026Total Debt (MRQ)
524.10MCNY77.94M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6029xvs Biotechnology peers
Current Ratio (MRQ)
1.29xvs Biotechnology peers
Book Value per Share (MRQ)
2.29CNYUpdated Aug 21, 2026Total Assets
2.02BCNY300.85M · vs all stocks (USD)
Total Current Assets
996.33MCNYFY2025 · Dec 31, 2025Total Liabilities
1.12BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.03BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
382.02MCNYFY2025 · Dec 31, 2025Total Current Liabilities
737.07MCNYFY2025 · Dec 31, 2025Cash
246.25MCNYFY2025 · Dec 31, 2025Cash Equivalents
357.14KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
246.61MCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.60MCNYFY2025 · Dec 31, 2025Accounts Receivable
655.57MCNYFY2025 · Dec 31, 2025Inventory
62.38MCNYFY2025 · Dec 31, 2025Accounts Payable
153.07MCNYFY2025 · Dec 31, 2025Short-term Debt
102.06MCNYFY2025 · Dec 31, 2025Other Current Liabilities
29.59KCNYFY2025 · Dec 31, 2025Long-term Debt
330.97MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
13.48MCNYFY2025 · Dec 31, 2025Common Stock (Book)
405.71MCNYFY2025 · Dec 31, 2025Retained Earnings
-77.63MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
903.98MCNY134.43M · vs all stocks (USD)
Treasury Stock
3.17MCNYFY2025 · Dec 31, 202552-Week Low
20.41CNYUpdated Aug 21, 202652-Week High
44.90CNYUpdated Aug 21, 202652-Week Change
-9.41%vs all stocks
50-Day MA
32.46CNYUpdated Aug 21, 2026200-Day MA
29.56CNYUpdated Aug 21, 2026Avg 10-Day Volume
9.56MSharesUpdated Aug 21, 2026Avg 30-Day Volume
12.60MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.0600CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 16.17Revenue Growth YoY: -0.07
High gross margins eroded by operating costsNotable
Gross Margin: 0.92Profit Margin: -0.03
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.89
Altman Z-Score 7.07: safe zoneNotable
Altman Z-Score: 7.07
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.82B, above the global median of $1.15BNotable
Market cap (USD): 1,815,284,235.96Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bicara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhuzhou Hongda Electronics Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked ROA and Margin Elevated
Juneway Electronic Technology Co.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked ROA and Margin Elevated
GCH Technology Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked ROA and Margin Elevated